10-K/A: Boston Scientific Files Amended 10-K to Correct Auditor's Signature

Boston Scientific Corporation filed an amendment to its annual report to include the conformed electronic signature of its independent auditor, Ernst & Young LLP.

Summary

• Boston Scientific Corporation filed an amendment to its annual report on Form 10-K for the fiscal year ended December 31, 2023.
• The amendment was made solely to correct an omission in Exhibit 23, the Consent of Independent Registered Public Accounting Firm.
• The original filing on February 20, 2024, inadvertently omitted the conformed electronic signature of Ernst & Young LLP.
• The company is amending the filing to include the executed copy of the consent with the correct signature.
• There are no other changes to the original Form 10-K or the consent.

Sentiment

Score: 7

Explanation: The document is a routine amendment to correct a minor error, which is a neutral event. The company acted promptly to rectify the issue, which is a positive sign.

Positives

• The company promptly addressed the error in the original filing by submitting an amendment.
• The amendment ensures compliance with SEC regulations regarding auditor consent.

Risks

• While this amendment is minor, any errors in filings can raise concerns about internal controls.
• The need for an amendment, even for a minor issue, could potentially impact investor confidence.

Management Comments

• Michael F. Mahoney, Chief Executive Officer, certified that the report does not contain any untrue statement of a material fact.
• Daniel J. Brennan, Executive Vice President and Chief Financial Officer, certified that the report does not contain any untrue statement of a material fact.

Industry Context

This is a standard regulatory filing amendment, and the issue is not specific to the medical device industry. It is a procedural correction.

Comparison to Industry Standards

• The need for an amendment to correct an auditor's signature is not unique to Boston Scientific and can occur in any company's filings.
• Other large public companies such as Medtronic and Abbott also file similar 10-K reports and amendments as required by the SEC.

Stakeholder Impact

• The amendment has a minimal impact on stakeholders as it is a procedural correction.
• Shareholders may view the prompt correction as a sign of good corporate governance.

Key Dates

Keywords

Form 10-K, Amendment, Auditor Consent, Ernst & Young, SEC Filing, Financial Reporting, Boston Scientific